Jan van der Weide

3.7k total citations · 2 hit papers
47 papers, 2.8k citations indexed

About

Jan van der Weide is a scholar working on Pharmacology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jan van der Weide has authored 47 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pharmacology, 17 papers in Molecular Biology and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jan van der Weide's work include Pharmacogenetics and Drug Metabolism (24 papers), Schizophrenia research and treatment (10 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Jan van der Weide is often cited by papers focused on Pharmacogenetics and Drug Metabolism (24 papers), Schizophrenia research and treatment (10 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Jan van der Weide collaborates with scholars based in Netherlands, United Kingdom and United States. Jan van der Weide's co-authors include Linda S. W. Steijns, Henk‐Jan Guchelaar, Bob Wilffert, Marga Nijenhuis, Jesse J. Swen, Gerard A. Rongen, Ron H. N. van Schaik, Vera H.M. Deneer, Daan J. Touw and Anthonius de Boer and has published in prestigious journals such as Journal of Medicinal Chemistry, Clinical Chemistry and European Journal of Pharmacology.

In The Last Decade

Jan van der Weide

47 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

2011 747 citations Jesse J. Swen, Marga Nijenhuis et al. Clinical Pharmacology & Therapeutics profile →
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

2023 71 citations Marga Nijenhuis, Bianca Soree et al. European Journal of Human Genetics profile →

Peers

Countries citing papers authored by Jan van der Weide

Since Specialization

Citations

This map shows the geographic impact of Jan van der Weide's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan van der Weide with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan van der Weide more than expected).

Fields of papers citing papers by Jan van der Weide

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan van der Weide. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan van der Weide. The network helps show where Jan van der Weide may publish in the future.

Co-authorship network of co-authors of Jan van der Weide

This figure shows the co-authorship network connecting the top 25 collaborators of Jan van der Weide. A scholar is included among the top collaborators of Jan van der Weide based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan van der Weide. Jan van der Weide is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics breakdown → 2023 ·European Journal of Human Genetics ·(unknown), Marga Nijenhuis, Bianca Soree, Nienke J. de Boer‐Veger, Anne‐Marie Buunk, Henk‐Jan Guchelaar, Elisa J. F. Houwink, Arne Risselada, Gerard A. Rongen, Ron H. N. van Schaik, Jesse J. Swen, Daan J. Touw, Roos van Westrhenen, Vera H.M. Deneer, Jan van der Weide	71
2	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs 2021 ·European Journal of Human Genetics ·J. Brouwer, Marga Nijenhuis, Bianca Soree, Henk‐Jan Guchelaar, Jesse J. Swen, Ron H. N. van Schaik, Jan van der Weide, Gerard A. Rongen, Anne‐Marie Buunk, Nienke J. de Boer‐Veger, Elisa J. F. Houwink, Roos van Westrhenen, Bob Wilffert, Vera H.M. Deneer, Hans Mulder	78
3	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone) 2021 ·European Journal of Human Genetics ·Maja Matić, Marga Nijenhuis, Bianca Soree, Nienke J. de Boer‐Veger, Anne‐Marie Buunk, Elisa J. F. Houwink, Hans Mulder, Gerard A. Rongen, Jan van der Weide, Bob Wilffert, Jesse J. Swen, Henk‐Jan Guchelaar, Vera H.M. Deneer, Ron H. N. van Schaik	31
4	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines 2019 ·European Journal of Human Genetics ·Carin A.T.C. Lunenburg, Cathelijne H. van der Wouden, Marga Nijenhuis, (unknown), Nienke J. de Boer‐Veger, Anne M. Buunk, Elisa J. F. Houwink, Hans Mulder, Gerard A. Rongen, Ron H. N. van Schaik, Jan van der Weide, Bob Wilffert, Vera H.M. Deneer, Jesse J. Swen, Henk‐Jan Guchelaar	153
5	Pharmacogenetic Information in Clinical Guidelines: The European Perspective 2018 ·Clinical Pharmacology & Therapeutics ·Jesse J. Swen, Marga Nijenhuis, (unknown), Nienke J. de Boer‐Veger, Anne‐Marie Buunk, Elisa J. F. Houwink, Hans Mulder, Gerard A. Rongen, Ron H. N. van Schaik, Jan van der Weide, Bob Wilffert, Vera H.M. Deneer, Henk‐Jan Guchelaar	69
6	Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population 2016 ·The Pharmacogenomics Journal ·Karen van der Weide, Harriët M. Loovers, Kirsten M. Pondman, Jan Bogers, Tahar van der Straaten, Ellen Langemeijer, Daniel Cohen, Jan N. M. Commandeur, Jan van der Weide	23
7	The association between CYP2D6 genotype and switching antipsychotic medication to clozapine 2013 ·European Journal of Clinical Pharmacology ·(unknown), Karen van der Weide, Jan van der Weide, Harold J.G.M. van Megen, Toine C. G. Egberts, Eibert R. Heerdink	3
8	Association between LEP and LEPR gene polymorphisms and dyslipidemia in patients using atypical antipsychotic medication 2010 ·Psychiatric Genetics ·(unknown), Jan van der Weide, Harriët M. Loovers, (unknown), Toine C. G. Egberts, Eibert R. Heerdink	18
9	Association between CYP2C1917 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients 2010 ·The Pharmacogenomics Journal* ·A. De Vos, Jan van der Weide, Harriët M. Loovers	50
10	Combined HTR2C-LEP Genotype as a Determinant of Obesity in Patients Using Antipsychotic Medication 2010 ·Journal of Clinical Psychopharmacology ·(unknown), Hans Mulder, Dan Cohen, Harold J.G.M. van Megen, Toine C. G. Egberts, Eibert R. Heerdink, Jan van der Weide	18
11	Implementation of CYP2D6 genotyping in psychiatry 2009 ·Expert Opinion on Drug Metabolism & Toxicology ·Harriët M. Loovers, Jan van der Weide	13
12	Pharmacogenetics: From Bench to Byte 2008 ·Clinical Pharmacology & Therapeutics ·JJ Swen, Ingeborg Wilting, (unknown), (unknown), Johannes Mulder, Daan J. Touw, Anthonius de Boer, (unknown), Toine C. G. Egberts, (unknown), Richard P. Koopmans, Jan van der Weide, Bob Wilffert, Henk‐Jan Guchelaar, (unknown)	194
13	Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics 2008 ·European Journal of Clinical Pharmacology ·John W. J. Hinrichs, Harriët M. Loovers, (unknown), Jan van der Weide	18
14	D3 dopamine receptor mRNA expression in lymphocytes: a peripheral marker for schizophrenia? 2003 ·Acta Neuropsychiatrica ·Jan van der Weide, Linda S. W. Steijns, (unknown), (unknown)	3
15	Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case–control study 2002 ·Pharmacogenetics ·(unknown), Anthonius de Boer, Jan van der Weide, Linda S. W. Steijns, Raymund A.C. Roos, Paul A.F. Jansen, Hubert G.M. Leufkens	53
16	Evaluation of Fluorescence Polarization Assays for Measuring Valproic Acid, Phenytoin, Carbamazepine and Phenobarbital in Serum 2002 ·Therapeutic Drug Monitoring ·Linda S. W. Steijns, (unknown), Jan van der Weide	19
17	Evaluation of the Cloned Enzyme Donor Immunoassay for Measurement of Phenytoin and Phenobarbital in Serum 1993 ·Therapeutic Drug Monitoring ·Jan van der Weide, (unknown), (unknown)	3
18	The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors 1988 ·European Journal of Pharmacology ·Jan van der Weide, (unknown), Pieter G. Tepper, Jan B. De Vries, Margarita L. Dubocovich, Alan S. Horn	35
19	N-0437:a selective D-2 dopamine receptor agonist in in vitro and in vivo models 1988 ·European Journal of Pharmacology ·Jan van der Weide, Jan B. De Vries, Pieter G. Tepper, Diana N. Krause, Margarita L. Dubocovich, (unknown)	40
20	Synthesis and pharmacology of trans-4-n-propyl-3,4,4a,10b-tetrahydro-2H,5H-1-benzopyrano[4,3-b]1,4-oxazin-7- and -9-ols. The significance of nitrogen pka values for central dopamine receptor activation 1988 ·Journal of Medicinal Chemistry ·Durk Dijkstra, (unknown), Hans Rollema, Pieter G. Tepper, Jan van der Weide, Alan S. Horn	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact